2021 American Transplant Congress
Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…2021 American Transplant Congress
Tacrolimus Therapeutic Exposure is Not Consistently Predicted by Target Troughs or CYP3A5 Variants in Stable Renal Transplant Recipients
*Purpose: Tacrolimus (TAC) immunosuppression requires therapeutic trough monitoring post-transplant due to notable interpatient pharmacokinetic(PK) variability which may be attributed to CYP3A5 polymorphisms. We investigated the…2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…2021 American Transplant Congress
Evaluation of Conversion to Extended-Release Tacrolimus in Abdominal Organ and Thoracic Transplant Recipients
*Purpose: An established approach for conversion from immediate-release tacrolimus (IR TAC) to extended-release tacrolimus (LCPT) in kidney transplantation exists, but is lacking in other organ…2021 American Transplant Congress
Avoiding Tacrolimus Under- and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial
*Purpose: Bodyweight-based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meagre 38% of patients is…2021 American Transplant Congress
Evaluation of Empiric Extended-Release Tacrolimus Dosing in Adult Kidney Transplant Recipients
Pharmacy, NewYork-Presbyterian Hospital, New York, NY
*Purpose: Envarsus XR® (extended-release [XR] tacrolimus) is the standard of care tacrolimus formulation at our center for de novo maintenance immunosuppression in adult kidney transplant…2021 American Transplant Congress
Quantifying the Interaction Between Posaconazole and Tacrolimus in Liver Transplant Recipients: A Practical Approach
*Purpose: The interaction between tacrolimus (FK) and posaconazole (POSA) is well documented, however the extent of this interaction and the practical management has yet to…2021 American Transplant Congress
Therapeutic Enoxaparin Dosing in Lung Transplant Recipients
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Enoxaparin 1 mg/kg subcutaneously every 12 hours for therapeutic anticoagulation is known to increase rates of supratherapeutic anti-Xa levels in lung transplant recipients (LTRs).…2020 American Transplant Congress
De Novo Dosing of LCP-Tacrolimus Using Conservative Weight-Based Strategy Resulted in Supratherapeutic Trough Levels in Majority of Patients
University of Virginia Health System, Charlottesville, VA
*Purpose: Due to ongoing national drug shortages, our center transitioned to de novo use of LCP-tacrolimus (LCPT) in kidney transplant patients using a conservative dosing…2020 American Transplant Congress
Natural History of Tacrolimus Intrapatient Variability During the First Post-Transplant Year
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: High tacrolimus intrapatient variability (IPV) is associated with inferior outcomes in solid organ transplantation. Many evaluations of IPV empirically exclude the early post-transplant period…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »